pathological myopia
Conditions
Interventions
pathological myopia group:no
rhegmatogenous retinal detachment or idiopathic macular hole group:no
Sponsors
Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for the observation group: (1) Patients diagnosed with pathological myopia with clear clinical indications for vitrectomy; (2) Aged over 40 years old; (3) Willing to participate in this trial and agree to sign the informed consent. 2. Inclusion criteria for the control group: (1) Diagnosed with rhegmatogenous retinal detachment with clinical indications for vitrectomy; (2) Aged over 40 years old; (3) Willing to participate in this trial and agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Exclusion criteria for observation group: (1) Patients with a history of intravitreal injection of any anti-vascular endothelial growth factor drugs, eye surgery or retinal photocoagulation; (2) History of previous eye diseases: such as patients with keratopathy, glaucoma, dacryocystitis, uveitis, eye trauma and age-related macular degeneration; (3) Combined with diabetes, fasting blood glucose > 8.5mmol/L or/and postprandial >10mmol/L; (4) Renal failure (plasma creatinine >= 120 µM), nephrotic syndrome or laboratory tests for albuminuria and proteinuria; (5) Combined with other chronic diseases or serious systemic diseases such as uncontrolled hypertension (diastolic blood pressure>90mmHg or/and systolic blood pressure>150mmHg), severe cardiac insufficiency, cerebrovascular accident, etc.; (6) People with abnormal coagulation function (those who take aspirin should stop for at least 1 week); (7) Patients with systemic immunosuppressants or corticosteroids; (8) Pregnant women; (9) The investigator evaluates patients who cannot complete the trial or who have other contraindications to surgery. 2. Exclusion criteria for the control group: (1) Secondary macular hole or retinal detachment; (2) Patients with previous intravitreal injection of any anti-vascular endothelial growth factor drugs, history of eye surgery or history of retinal laser photocoagulation; (3) History of previous eye diseases: such as patients with keratopathy, glaucoma, dacryocystitis, uveitis, eye trauma and age-related macular degeneration; (4) Combined with diabetes mellitus, fasting blood glucose > 8.5mmol/L or/and postprandial > 10mmol/L; (5) Renal failure (plasma creatinine >= 120 µM), nephrotic syndrome or laboratory tests for microalbuminuria and proteinuria; (6) Combined with other chronic diseases or serious systemic diseases such as uncontrolled hypertension (diastolic blood pressure>90mmHg or/and systolic blood pressure>150mmHg), severe cardiac insufficiency, cerebrovascular accident, etc.; (7) People with abnormal coagulation function (those who take aspirin should stop for at least 1 week); (8) Patients with systemic immunosuppressants or corticosteroids; (9) Pregnant women; (10) The investigator evaluates patients who cannot complete the trial or who have other contraindications to surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteomics and Metabolomics; | — |
Countries
China
Contacts
Public ContactHanyi Min
Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed